# Daily Iteration Report — 2026-06-06 (Saturday)

## Work queue items processed: 4

### 1. Git lock cleanup & local commit (priority 1)
The recurring fuse-mount lock issue blocked git again: `.git/HEAD.lock` and `.git/index.lock`
could not be removed with `rm` ("Operation not permitted" on the virtiofs mount) but were
successfully moved aside with `mv`. After clearing, the working-tree snapshot committed locally
(commit `bca4a0e`).

**Push remains blocked — requires the user.** `git push --dry-run origin main` fails with
`could not read Username for 'https://github.com'`: the sandbox HTTPS remote has no credential
helper / stored token. **35 commits are unpushed.** The user needs to run `git push origin main`
on the host machine (where credentials exist).

### 2. Path validation — 6 paths validated (priority 4)
Validated six previously-unvalidated research paths against external evidence:

| Path | Rating | Key external evidence |
|------|--------|----------------------|
| hydroxychloroquine → T2D | VALIDATED | SR/MA 11 RCTs, n=2723: HbA1c −0.19% (p=0.03), FPG −8.05 mg/dl (PMC9196294). Caveat: ~54% of RCTs poor Jadad quality. |
| metformin → T2D | VALIDATED | UKPDS 34 (PMID 9742977): any diabetes endpoint −32%, all-cause mortality −36%. ADA/EASD first-line. |
| dapagliflozin → T2D | VALIDATED | Monotherapy MA, 6 RCTs n=2033: HbA1c −0.60% vs placebo (PMID 31348290). |
| pioglitazone → T2D | VALIDATED | Add-on-to-insulin MA, n=3092: HbA1c −0.58%, p<0.00001 (PMC2701605). |
| NLRP3_inflammasome → nephropathy | VALIDATED (mechanistic) | mtROS–TXNIP/NLRP3 podocyte + tubular injury, IL-1β/IL-18, pyroptosis (PMC9218738, PMC12395217). **No NLRP3-inhibitor RCT in diabetic nephropathy yet — clinical efficacy unproven.** |
| verapamil → T1D | PARTIALLY_VALIDATED | CLVer pediatric: C-peptide +30% vs placebo at 52wk (positive). Ver-A-T1D adults: EASD 2025 trend but **missed significance marginally**, pub pending. |

Concretely-rated paths: 14 → **20**.

### 3. Credibility sweep (every run) — CLEAN
- No fabricated PMIDs ≥ 42,000,000 in any script.
- No "zero SAEs / zero rejection" overstatements.
- "achieves" matches all legitimate: TTP399 tissue selectivity (mechanism), LADA cost-effectiveness
  model output, microbiome ML macro-AUC metric.
- "curative" appears only inside `verify_before_deploy.py`'s own red-flag pattern definition
  (known false positive).

### 4. Pipeline rebuild (every run) — 41/41 [OK]
`run_quality_improvements.py`: all 41 improvements completed successfully.

## Notes
- All 285 papers remain vetted (272 VETTED / 13 FLAGGED) — no vetting backlog.
- Not Monday → weekly new-paper PubMed scan skipped (next due Monday 2026-06-08).
- No new PMIDs added to corpus this run.

## Next run priorities
1. **User action:** push the 35 local commits.
2. Continue path validation: dapagliflozin→inflammation, NF_kB→inflammation,
   empagliflozin→inflammation, oxidative_stress→cardiovascular, dorzagliatin→T2D.
3. Monday 2026-06-08: weekly new-paper sweep (LADA, islet transplant, NLRP3-DKD, drug repurposing,
   verapamil T1D, dapagliflozin+colchicine).
